450 related articles for article (PubMed ID: 31703717)
21. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
Singh N; Gold LS; Lee J; Wysham KD; Andrews JS; Makris UE; England BR; George MD; Baker JF; Jarvik J; Heagerty PJ; Singh S
Arthritis Care Res (Hoboken); 2024 May; 76(5):627-635. PubMed ID: 38116680
[TBL] [Abstract][Full Text] [Related]
22. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
23. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis.
Mohamed Ahamada M; Wu X
Clin Exp Rheumatol; 2023 Sep; 41(9):1882-1900. PubMed ID: 36912326
[TBL] [Abstract][Full Text] [Related]
24. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
25. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
[TBL] [Abstract][Full Text] [Related]
26. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
[TBL] [Abstract][Full Text] [Related]
27. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
Montastruc F; Renoux C; Hudson M; Dell'Aniello S; Simon TA; Suissa S
Semin Arthritis Rheum; 2019 Jun; 48(6):1053-1058. PubMed ID: 30772001
[TBL] [Abstract][Full Text] [Related]
28. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
29. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
30. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
de Germay S; Bagheri H; Despas F; Rousseau V; Montastruc F
Rheumatology (Oxford); 2020 Sep; 59(9):2360-2367. PubMed ID: 31880308
[TBL] [Abstract][Full Text] [Related]
31. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
32. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with mental illness in patients with rheumatoid arthritis initiating b/ts DMARDs: A population-based study.
Chen HH; Wu PY; Lin CH; Wu CL; Chao WC
Int J Rheum Dis; 2024 Jan; 27(1):e14992. PubMed ID: 38061767
[TBL] [Abstract][Full Text] [Related]
35. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
36. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
[TBL] [Abstract][Full Text] [Related]
37. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
38. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
39. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
[TBL] [Abstract][Full Text] [Related]
40. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
